Gilead Sciences (NASDAQ:GILD - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of $1.99 per share and revenue of $6.95 billion for the quarter.
Gilead Sciences Price Performance
NASDAQ GILD traded up $0.89 on Friday, hitting $113.18. The company had a trading volume of 5,016,320 shares, compared to its average volume of 5,285,206. The company has a market capitalization of $140.79 billion, a PE ratio of 23.83, a PEG ratio of 0.71 and a beta of 0.33. The company's fifty day moving average price is $110.51 and its 200-day moving average price is $106.70. Gilead Sciences has a 12-month low of $72.43 and a 12-month high of $119.96. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23.
Insider Buying and Selling
In related news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction on Monday, June 30th. The stock was sold at an average price of $110.45, for a total value of $1,104,500.00. Following the completion of the transaction, the chief executive officer owned 615,725 shares in the company, valued at $68,006,826.25. This trade represents a 1.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total value of $277,575.00. Following the completion of the sale, the chief financial officer directly owned 162,610 shares of the company's stock, valued at approximately $18,054,588.30. This represents a 1.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 82,000 shares of company stock worth $8,984,175. Company insiders own 0.27% of the company's stock.
Institutional Investors Weigh In On Gilead Sciences
A hedge fund recently raised its stake in Gilead Sciences stock. Brighton Jones LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 20.6% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 14,359 shares of the biopharmaceutical company's stock after buying an additional 2,450 shares during the period. Brighton Jones LLC's holdings in Gilead Sciences were worth $1,326,000 as of its most recent filing with the SEC. Institutional investors own 83.67% of the company's stock.
Wall Street Analyst Weigh In
GILD has been the topic of several recent research reports. Oppenheimer lowered their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price on the stock. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research note on Friday, July 25th. Finally, Morgan Stanley boosted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Eight research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $112.36.
Check Out Our Latest Research Report on GILD
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
